Tags

Type your tag names separated by a space and hit enter

Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
Eur J Gastroenterol Hepatol 2013; 25(7):798-805EJ

Abstract

OBJECTIVES

Previous studies, mostly retrospective using conventional interferon, have suggested a favorable prognosis for patients with chronic hepatitis C and a sustained virological response (SVR). However, long-term outcome, including changes in the degree of hepatic fibrosis, of SVR patients in the era of pegylated interferon (PegIFN) remains underdefined. We prospectively evaluated the long-term virological, clinical, and biochemical outcomes, including aspartate aminotransferase-to-platelet ratio index (APRI), in chronic hepatitis C patients with an SVR.

PATIENTS AND METHODS

We included 145 consecutive, treatment-naive chronic hepatitis C patients (mean age 47.3±9.1 years; 87 men; 42.1% genotype 1; 36.6% genotype 2/3) who achieved an SVR after combination therapy with PegIFN-α/ribavirin.

RESULTS

The mean follow-up time was 68.8±35 months. The overall incidence of hepatocellular carcinoma (HCC) and liver-related death was 1.4 and 0.7%, respectively. Among nine (7.6%) patients with pretreatment cirrhosis, two (22.2%) developed HCC and one of them (11.1%) died. No patient had conclusive evidence of late virological relapse. All patients retained normal liver biochemistry, except for five of 145 (3.5%), who had persistently elevated transaminase levels, all of whom were diagnosed with new liver disease. APRI values improved significantly with treatment (0.95±1.09 vs. 0.66±0.64, P<0.001) and continued to improve after a mean of 61.4±45.5 months from an SVR in patients (n=54; 37.2%) with significant (Metavir ≥F2) pretreatment fibrosis (1.13±0.66 vs. 0.67±0.45, P<0.001).

CONCLUSION

The long-term outcome, including APRI, of chronic hepatitis C patients treated successfully with PegIFN/ribavirin and followed for a mean of 5.7 years is favorable. However, a high risk of progression to HCC and liver-related death remains for patients with pretreatment cirrhosis, in our setting, as high as 22.2 and 11.1%, respectively.

Authors+Show Affiliations

Liver Clinic, First Department of Internal Medicine, General Hospital of Rhodes, Rhodes, Greece. vasi.pap@hotmail.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

23395996

Citation

Papastergiou, Vasilios, et al. "Durability of a Sustained Virological Response, Late Clinical Sequelae, and Long-term Changes in Aspartate Aminotransferase to the Platelet Ratio Index After Successful Treatment With Peginterferon/ribavirin for Chronic Hepatitis C: a Prospective Study." European Journal of Gastroenterology & Hepatology, vol. 25, no. 7, 2013, pp. 798-805.
Papastergiou V, Stampori M, Lisgos P, et al. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study. Eur J Gastroenterol Hepatol. 2013;25(7):798-805.
Papastergiou, V., Stampori, M., Lisgos, P., Pselas, C., Prodromidou, K., & Karatapanis, S. (2013). Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study. European Journal of Gastroenterology & Hepatology, 25(7), pp. 798-805. doi:10.1097/MEG.0b013e32835eb8bf.
Papastergiou V, et al. Durability of a Sustained Virological Response, Late Clinical Sequelae, and Long-term Changes in Aspartate Aminotransferase to the Platelet Ratio Index After Successful Treatment With Peginterferon/ribavirin for Chronic Hepatitis C: a Prospective Study. Eur J Gastroenterol Hepatol. 2013;25(7):798-805. PubMed PMID: 23395996.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study. AU - Papastergiou,Vasilios, AU - Stampori,Maria, AU - Lisgos,Phillipos, AU - Pselas,Crisostomos, AU - Prodromidou,Kleopatra, AU - Karatapanis,Stylianos, PY - 2013/2/12/entrez PY - 2013/2/12/pubmed PY - 2014/1/15/medline SP - 798 EP - 805 JF - European journal of gastroenterology & hepatology JO - Eur J Gastroenterol Hepatol VL - 25 IS - 7 N2 - OBJECTIVES: Previous studies, mostly retrospective using conventional interferon, have suggested a favorable prognosis for patients with chronic hepatitis C and a sustained virological response (SVR). However, long-term outcome, including changes in the degree of hepatic fibrosis, of SVR patients in the era of pegylated interferon (PegIFN) remains underdefined. We prospectively evaluated the long-term virological, clinical, and biochemical outcomes, including aspartate aminotransferase-to-platelet ratio index (APRI), in chronic hepatitis C patients with an SVR. PATIENTS AND METHODS: We included 145 consecutive, treatment-naive chronic hepatitis C patients (mean age 47.3±9.1 years; 87 men; 42.1% genotype 1; 36.6% genotype 2/3) who achieved an SVR after combination therapy with PegIFN-α/ribavirin. RESULTS: The mean follow-up time was 68.8±35 months. The overall incidence of hepatocellular carcinoma (HCC) and liver-related death was 1.4 and 0.7%, respectively. Among nine (7.6%) patients with pretreatment cirrhosis, two (22.2%) developed HCC and one of them (11.1%) died. No patient had conclusive evidence of late virological relapse. All patients retained normal liver biochemistry, except for five of 145 (3.5%), who had persistently elevated transaminase levels, all of whom were diagnosed with new liver disease. APRI values improved significantly with treatment (0.95±1.09 vs. 0.66±0.64, P<0.001) and continued to improve after a mean of 61.4±45.5 months from an SVR in patients (n=54; 37.2%) with significant (Metavir ≥F2) pretreatment fibrosis (1.13±0.66 vs. 0.67±0.45, P<0.001). CONCLUSION: The long-term outcome, including APRI, of chronic hepatitis C patients treated successfully with PegIFN/ribavirin and followed for a mean of 5.7 years is favorable. However, a high risk of progression to HCC and liver-related death remains for patients with pretreatment cirrhosis, in our setting, as high as 22.2 and 11.1%, respectively. SN - 1473-5687 UR - https://www.unboundmedicine.com/medline/citation/23395996/Durability_of_a_sustained_virological_response_late_clinical_sequelae_and_long_term_changes_in_aspartate_aminotransferase_to_the_platelet_ratio_index_after_successful_treatment_with_peginterferon/ribavirin_for_chronic_hepatitis_C:_a_prospective_study_ L2 - http://dx.doi.org/10.1097/MEG.0b013e32835eb8bf DB - PRIME DP - Unbound Medicine ER -